Table 1. Baseline Patient Demographic and Clinical Characteristics.
| Characteristic | Group, No. (%) | |
|---|---|---|
| Docetaxel (n = 217) | Carboplatin-pemetrexed (n = 216) | |
| Age, median (range), y | 78 (75-88) | 78 (75-88) |
| Age ≥80 y | 56 (25.8) | 51 (23.6) |
| Sex | ||
| Male | 126 (58.1) | 124 (57.4) |
| Female | 91 (41.9) | 92 (42.6) |
| ECOG performance status | ||
| 0 | 85 (39.2) | 91 (42.1) |
| 1 | 132 (60.8) | 125 (57.9) |
| Clinical stage | ||
| III | 16 (7.4) | 14 (6.5) |
| IV | 164 (75.6) | 161 (74.5) |
| Recurrent | 37 (17.1) | 41 (19.0) |
| Smoking status | ||
| Smoker | 128 (59.0) | 130 (60.2) |
| Never | 89 (41.0) | 86 (39.8) |
| EGFR variant status | ||
| Negative | 165 (76.0) | 160 (74.1) |
| Positive | 47 (21.7) | 48 (22.2) |
| Unknown | 5 (2.3) | 8 (3.7) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor.